Pfizer Vaccine Preparation

Lyme disease vaccine 70 percent effective

Pfizer will seek approval for its Lyme disease vaccine

Pfizer said its experimental Lyme disease vaccine was more than 70% efficacious in reducing confirmed cases of the tickborne illness in a phase 3 trial, although the trial missed its primary endpoint.

· 1d · on MSN

Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss

· 1d · on MSN

Lyme disease vaccine shows 70 percent efficacy, Pfizer says

· 23h

Pfizer Lyme Disease Vaccine Shows 70% Efficacy, But Misses Statistical Goal

Pfizer and Valneva said on Monday their Lyme disease vaccine showed more than 70% efficacy in a late-stage study, even as it missed its main goal.

· 1d

Pfizer says Lyme disease vaccine is holding promise

· 1d

Pfizer-Valneva Lyme vaccine shows more than 70% efficacy but misses key goal

1don MSN

Pfizer’s Lyme Vaccine Shows Strong Efficacy, but Misses Mark in Study

The drugmaker is seeking regulatory review for the first new shot to combat the disease in decades.

Morning Overview on MSN

Pfizer, Valneva Lyme vaccine misses primary endpoint despite efficacy

Pfizer and Valneva’s experimental Lyme disease vaccine, VLA15, failed to meet the primary endpoint of its late-stage clinical trial, even though the shot demonstrated more than 70% efficacy against confirmed Lyme disease.